Clinical Trials Using Fluorothymidine F-18

Clinical trials are research studies that involve people. The clinical trials on this list are studying Fluorothymidine F-18. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-14 of 14
  • Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second or above Donor Stem Cell Transplant

    This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have returned after a period of improvement (relapsed) undergoing a second or above donor stem cell transplant. IMTMI is a type of radiation therapy to the bone marrow that may be less toxic and may also reduce the chances of cancer to return. Giving fludarabine phosphate, melphalan, and IMTMI before a donor stem cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • 18F-FLT PET Imaging in Assessing Tumors and Measuring Response in Younger Patients With Brain Tumors

    This phase II trial studies fluorine-18F-fluorothymidine (18F-FLT) positron emission tomography (PET) imaging in assessing tumors and measuring response in younger patients with brain tumors. Diagnostic procedures, such as fluorine 18F-fluorothymidine PET imaging, may help measure a patient's tumors and response to earlier treatment.
    Location: 6 locations

  • [18F]FLT PET / CT in Predicting Tumor Response to Chemotherapy in Pediatric Patients with Solid Tumors

    This trial studies how well [18F] FLT positron emission tomography (PET) / computed tomography (CT) works in predicting tumor response to chemotherapy in pediatric patients with solid tumors. Diagnostic procedures, such as [18F]FLT PET / CT, may measure dividing (or growing) cells in the tumor and may help predict whether the tumor will progress after therapy.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • 18-FLT PET / MRI in Predicting Graft Failure and Graft Versus Host Disease in Patients Undergoing Bone Marrow or Stem Cell Transplant

    This early phase I trial studies how well fluorothymidine F-18 (18-FLT) positron emission tomography (PET) / magnetic resonance imaging (MRI) works in predicting graft failure and graft versus host disease in patients who are undergoing a bone marrow or stem cell transplant. FLT is a PET tracer that is used to image areas with high rates of cell division. Giving FLT with diagnostic procedures, such as PET / MRI, may help predict bone marrow transplant success, malignancy relapse, and the development of graft versus host disease.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Fluorothymidine F-18 PET / CT in Predicting Outcome in Participants with Locally Advanced Pancreatic Cancer

    This phase II trial studies how well fluorothymidine F-18 positron emission tomography (PET) / computed tomography (CT) works in predicting outcome in participants with pancreatic cancer that has spread to nearby tissue or lymph nodes. Fluorothymidine F-18 PET / CT may help in evaluating the type of cancer and predicting how well the cancer responds to therapy.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Fluorine F18 Fluciclovine and Fluorine F 18 Fluorothymidine PET / CT in Diagnosing Patients with High-Grade Brain Tumors

    This phase II trial studies how well fluorine f18 fluciclovine and fluorine f18 fluorothymidine PET / CT work in diagnosing patients with high-grade brain tumors. Diagnostic procedures, such as f18 fluciclovine and fluorine f18 fluorothymidine positron-emission tomography (PET) / computed tomography (CT), may help find and diagnose high-grade brain tumors and find out how far the disease has spread.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Dexamethasone Effects in Patients with Newly Diagnosed, Recurrent, or Progressive Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

    This pilot phase II trial studies the effects of dexamethasone in patients with non-small cell lung cancer that is newly diagnosed, has come back, or is growing, spreading, or getting worse. Drugs such as dexamethasone can affect how tumors grow and respond to treatments. Imaging tests, such as fluoro-L-thymidine (FLT) positron emission tomography, use a small amount of radioactive substance to show changes in tumor cells. Studying the effects of dexamethasone on lung tumors using FLT positron emission tomography may help doctors plan better treatments.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • [18F]Fluorothymidine PET / CT Imaging for Monitoring Treatment Response in Patients with Metastatic Breast Cancer Undergoing Treatment with Ribociclib and Paclitaxel

    This trial studies how well [18F]fluorothymidine PET / CT imaging works in measuring tumor growth and changes in the tumor after the start of treatment in patients with metastatic breast cancer undergoing treatment with ribociclib and paclitaxel. Positron emission tomography / computed tomography (PET / CT) imaging is commonly used in staging cancers. [18F]-fluorothymidine (FLT) is a specialized radioactive drug that is used as an imaging agent for PET / CT scans that uses a small amount of radioactive material to image tissue using a PET / CT scanner which is specialized to detect a small radioactive signal. [18F]FLT is used to detect cell growth. [18F]FLT PET / CT may help determine if the tumor responds to therapy with ribociclib and paclitaxel and what changes occur in the tumor after each drug.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

    Background: - Many people with neurofibromatosis type 1 (NF1) get tumors of the nervous system. Finding malignant tumors early is important for removing them. Researchers want to find ways of doing this with scans and genetic testing. Objectives: - To learn more about neurofibromatosis type 1. Eligibility: - People age 10 and older with NF1 who have a benign tumor or have had a malignant one. Design: - Participants will be screened in another study with medical history, physical exam, and urine and blood tests. They will have a magnetic resonance imaging (MRI) scan. - MRI: Participants will lie on a table that slides into a metal cylinder. They will be in the scanner for 60 90 minutes, lying still for 15 minutes at a time. Participants will get earplugs for the loud sounds. They will get a contrast agent (dye) through a thin plastic tube (catheter) inserted in an arm vein. - As part of their regular care, participants will have: - FDG-PET / CT scan. They will get radioactive glucose (sugar) through a catheter in an arm vein. - [18F]-FLT-PET / CT scan. This is like the FDG scan but with a different radioactive chemical. - Biopsy. A piece of tumor tissue is removed with a needle. A piece of tissue from a previous biopsy may also be studied. - Participants may have genetic testing. Blood will be taken. It will be tested along with biopsy samples. Researchers will explain the risks and procedures. They may notify participants if testing shows health problems. - After this study, participants will continue their regular cancer care.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • [F-18] FLT PET in Measuring Tumor Response in Patients with Solid Tumors or Hematopoietic Cancer

    This pilot clinical trial studies fluorothymidine F-18 ([F-18] FLT) positron emission tomography (PET) in measuring tumor response in patients with solid tumors or a cancer of the blood or bone marrow, such as leukemia or lymphoma (hematopoietic cancer). Diagnostic procedures, such as fluorothymidine F-18 positron emission tomography, may help measure a patient's response to earlier treatment. Comparing results of diagnostic procedures done during or after chemotherapy may help doctors predict patient's response to treatment and help plan the best treatment.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • Multi-tracer PET in Imaging Patients with Brain Tumors

    This pilot clinical trial studies multi-tracer positron emission tomography (PET) in imaging patients with brain tumors. PET uses radioactive labels (tracer), such as fludeoxyglucose F 18 (18F-FDG), fluorine F 18 fluorothymidine (18F-FLT), carbon 11 acetate (11C-ACE), or oxygen 15 water (15O-H2O), which can recognize differences between tumor and healthy brain. Multi-tracer PET may help find tumor proliferation (movement), glucose metabolism (sugars), blood flow, and growth rate in order to better predict treatment response.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Fluorothymidine F-18 PET in Diagnosing Patients with Intermediate or High Grade Soft Tissue Sarcoma

    This pilot early phase I trial studies how well fluorothymidine F-18 positron emission tomography (PET) works in diagnosing patients with intermediate or high grade soft tissue sarcoma. Fluorothymidine F-18 PET may provide useful information about the tumor's response to treatment and may give the doctors early results that would better help to plan the post-surgical therapy.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • FLT-PET / MRI in Measuring Early Response in Patients with Metastatic Solid Tumors Receiving Treatment That Blocks Blood Flow to the Tumor

    This pilot clinical trial studies whether fluorine F 18 fluorothymidine (FLT) will enable positron emission tomography / magnetic resonance imaging (PET / MRI) to measure response earlier in patients with metastatic solid tumors who are receiving treatment with agents that reduce the growth of new blood vessels. Diagnostic procedures, such as FLT-PET / MRI, are used to measure a patient's response to earlier treatment.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients with Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

    This pilot clinical trial studies multi-modality imaging and collection of biospecimen samples in understanding bone marrow changes in patients with acute myeloid leukemia undergoing total body irradiation (TBI) and chemotherapy. Using mutli-modality imaging and collecting biospecimen samples may help doctors know more about how TBI and chemotherapy can change the bone marrow.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California